Harvard Bioscience

Yahoo Finance • 2 months ago

Judge orders Trump administration to restore part of UCLA's suspended funding

By Kanishka Singh and Nate Raymond WASHINGTON (Reuters) -A U.S. judge on Tuesday ordered President Donald Trump’s administration to restore a part of the federal grant funding that it recently suspended for the University of California, L... Full story

Yahoo Finance • 2 months ago

Harvard Bioscience outlines $19M–$21M Q3 revenue target as debt refinancing advances and product adoption accelerates

Earnings Call Insights: Harvard Bioscience (HBIO) Q2 2025 MANAGEMENT VIEW * John Duke, President and CEO, shared his initial observations as the new leader, stating he is "encouraged" by the company's operating team, innovation pipelin... Full story

Yahoo Finance • 2 months ago

Harvard Bioscience Inc (NASDAQ:HBIO) Reports Mixed Q2 2025 Earnings Amid Revenue Miss and Improved Cash Flow

Harvard Bioscience Inc (NASDAQ:HBIO [https://www.chartmill.com/stock/quote/HBIO/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company posted revenue of $20.... Full story

Yahoo Finance • 2 months ago

Harvard Bioscience stock holds Speculative Buy rating at Benchmark

Investing.com - Harvard Bioscience Inc. (NASDAQ:HBIO) has pre-announced second-quarter revenue of approximately $20.4 million, exceeding consensus expectations of $18.8 million, according to Benchmark. The company, currently trading at $0.... Full story

Yahoo Finance • 3 months ago

Harvard Bioscience announces CEO succession plan

* Harvard Bioscience (NASDAQ:HBIO [https://seekingalpha.com/symbol/HBIO]) announced [https://seekingalpha.com/pr/20169109-harvard-bioscience-announces-ceo-succession-plan-and-appointment-of-two-new-independent] a CEO succession plan unde... Full story

Yahoo Finance • 3 months ago

Harvard Bioscience names John Duke as new CEO as Jim Green retires

HOLLISTON, Mass. - Harvard Bioscience, Inc. (NASDAQ:HBIO) announced Thursday that board member John Duke will succeed Jim Green as President and CEO effective July 28, 2025, following Green’s planned retirement after more than eight years... Full story

Yahoo Finance • 3 months ago

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin... Full story

Yahoo Finance • 4 months ago

Harvard Bioscience Appoints John Duke to Board of Directors

HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the a... Full story

Yahoo Finance • 5 months ago

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call... Full story

Yahoo Finance • 6 months ago

Harvard Bioscience Announces CFO Transition

HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation wi... Full story

Yahoo Finance • 7 months ago

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two invest... Full story

Yahoo Finance • 7 months ago

Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, sa... Full story

Yahoo Finance • 7 months ago

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 17-20, 2025, i... Full story

Yahoo Finance • 7 months ago

Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conferenc... Full story

Yahoo Finance • 2 years ago

Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023

HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December... Full story

Yahoo Finance • 2 years ago

Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023

HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thurs... Full story

Yahoo Finance • 2 years ago

Harvard Bioscience Announces Third Quarter 2023 Financial Results

Q3Revenuesof$25.4 millionQ3GrossMarginof58.1%Q3GAAPoperatinglossof$0.9million,adjustedoperatingincome$1.8 millionContinuedstrongoperatingcashflowdrovedebtreduction of$8.3million through Q3 HOLLISTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE... Full story

Yahoo Finance • 2 years ago

Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023

HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2... Full story

Yahoo Finance • 2 years ago

Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research

Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI) Expands reach of unique, non-invasive wearable monitoring for pre-clinical research across North American and European... Full story

Yahoo Finance • 2 years ago

Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes

HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced that it is set to join the Russell 2000® and Russell 3000 Indexes, according to preliminary membership informatio... Full story